**TORREYA CAPITAL MARKETS:**
Raising Capital and Creating Liquidity for Healthcare Companies Worldwide

**REPRESENTATIVE CAPITAL MARKETS TRANSACTIONS**

<table>
<thead>
<tr>
<th>Company</th>
<th>Transaction Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubicon</td>
<td>Majority recap, $125 million, April 2013</td>
</tr>
<tr>
<td>Mustangio</td>
<td>Venture debt raise, $20 million, April 2019</td>
</tr>
<tr>
<td>saama</td>
<td>Financing, $40 million, March 2019</td>
</tr>
<tr>
<td>Mid-Atlantic</td>
<td>Credit facility, $70 million, January 2019</td>
</tr>
<tr>
<td>Tris</td>
<td>Debt recapitalization, $125 million, September 2018</td>
</tr>
<tr>
<td>XOMA</td>
<td>Royalty interest acquisition, $15 million, September 2018</td>
</tr>
<tr>
<td>Hyland</td>
<td>Termination from agenius, $40 million, June 2018</td>
</tr>
<tr>
<td>Undisclosed Physical Therapy Practice</td>
<td>Majority recap, $20 million, March 2018</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Debt financing, $15 million, January 2018</td>
</tr>
<tr>
<td>m</td>
<td>Loan agreement, $100 million, February 2016</td>
</tr>
<tr>
<td>Crown Laboratories, Inc.</td>
<td>Sale of majority equity stake, $17.5 million, December 2016</td>
</tr>
<tr>
<td>opiant</td>
<td>Sale of royalties to GWK Pharma, $40 million, September 2016</td>
</tr>
<tr>
<td>Teddy</td>
<td>Partial sale of royalty and milestones, $40 million, September 2016</td>
</tr>
<tr>
<td>TOPIX</td>
<td>Sale of majority stake to New Mountain Capital, $100 million, February 2016</td>
</tr>
<tr>
<td>Healthcare Royalty Partners</td>
<td>Acquisition credit facility, $100 million, February 2016</td>
</tr>
</tbody>
</table>

**PROVIDING CAPITAL FOR:**
- Growth, expansion
- Shareholder liquidity
- Acquisition financing

**THROUGH:**
- Term loans
- Structured credit
- Royalty monetizations
- Private equity

**DEDICATED CAPITAL MARKETS TEAM**
- Five professionals with nearly 75 years of combined markets and industry experience
- Raising private capital across the capital structure for commercial companies
- Monetizing royalty streams from products in all stages of development

For more information, please contact +1 212.257.5801

Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC.
In Europe, such services are offered through Torreya Partners (Europe) LLP, which is authorised and regulated by the UK Financial Conduct Authority.
TORREY CAPITAL MARKETS TEAM:

Tom Babich
HEAD OF CAPITAL MARKETS
NEW YORK OFFICE
tom.babich@torreya.com
T 212.257.5811  
c 646.919.5797

John D. Bradley
MANAGING DIRECTOR
NEW YORK OFFICE
john.bradley@torreya.com
T 212.257.5805  
c 917.297.8699

Tom Babich leads funding transactions in the United States, including private equity investments, debt placements and royalty monetizations. In addition to biotech and spec pharma, Tom focused on healthcare services and life sciences tools. Notable transactions on which Tom has worked include the Credit Facility for Mid-Atlantic, equity recap of Crown Labs, monetization of Bendeka for SciDose and the sale of Topix Pharmaceuticals to New Mountain Capital. Tom joined Torreya in 2009. Previously, he was a professional baseball player. He received a B.A. in economics from Harvard University. Tom is a director of Noria Therapeutics and is active with New York Cares and the Xaverian Brothers Alumni Association.

Anna A. Makki
MANAGING DIRECTOR
NEW YORK OFFICE
anna.makki@torreya.com
T 212.257.2825  
c 646.463.2158

Anna A. Makki has over 14 years of experience in investment banking and capital markets. Before joining Torreya, Anna was a Director in Credit Suisse’s Esoteric Asset Finance group within Global Markets, where she was responsible for building a financing platform focused on assets backed by intellectual property. Previously, she was an Executive Director at Morgan Stanley in Global Capital Markets and Investment Banking and started her investment banking career at Banc of America Securities. She holds an M.B.A. from the Wharton School and an M.A. in international relations from the J. Lauder Institute at the University of Pennsylvania. Additionally, Anna has her B.A., magna cum laude, in mathematics and business administration from Franklin & Marshall College.

Nicola Benatti
ANALYST
NEW YORK OFFICE
nicola.benatti@torreya.com
T 212.257.6037  
c 718.883.0756

Nicola Benatti joined Torreya in 2017. Notable deals he has worked on include the Hyland’s term loan, as well as the debt recapitalization and acquisition of NextWave Pharmaceuticals by Tris Pharmaceuticals, both in 2018. Previously, he worked as an investment banking Analyst in Capital Markets and M&A at CastleOak Securities, a subsidiary of Cantor Fitzgerald. Nicola also interned in CPL Concordia’s Beijing office, and at AIG in New York City. He earned his B.A. degree with a double major in economics and mathematics from New York University. He is a native Italian speaker and is fluent in Spanish.

Recent Team Deal Highlights:

- **April 2019:** Torreya arranged a $20 million venture debt financing agreement between Mustang Bio and Horizon Technology Finance Corporation, providing Mustang Bio with additional working capital to develop their gene and cell therapies in their cell processing facility.
- **March 2019:** Torreya served as the financial advisor to Saama Technologies, a leading clinical data analytics platform firm, as they secured a $40mn financing from Perceptive Advisors to support the expansion of Saama’s Life Science Analytics Cloud (LSAC), an AI-powered platform to disrupt the planning, designing and conduct of clinical trials across the various stages of clinical development.
- **January 2019:** Torreya arranged a $70mn credit facility with CRG to finance Mid-Atlantic Dental’s acquisition of Birner Dental Management.
- **September 2018:** Torreya facilitated Tris Pharmaceuticals’ $125mn debt recapitalization provided by Deerfield allowing for the acquisition of Next Wave Pharmaceuticals from Pfzer, ultimately expanding Tris’ branded pharmaceutical portfolio with a particular focus on ADHD and continuing development of Tris’ proprietary drug development platform.